Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)
Sponsor: Bristol-Myers Squibb
A PHASE4 clinical study on Psoriasis, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 18 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE4
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Dec 2024 — Apr 2025 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 13 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
-
Dec 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Dec 2023 [monthly]
Recruiting PHASE4
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE4
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE4
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE4
Phase: PHASE3 → PHASE4
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .